KRAS and non-small cell lung carcinoma: The biomarkers for targeted therapies in NSCLC predominantly serve a predictive function, shedding light on therapeutic outcomes, while a smaller subset acts as prognostic indicators, gauging overall survival prospects (such as KRAS mutations), though the delineation between the two is not absolute.